Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells

Oncotarget (2016)

Dominika Piasecka Kamila Kitowska Dominika Czaplińska Kamil Mieczkowski Magdalena Mieszkowska Lukasz Turczyk Andrzej C. Składanowski Anna J. Żaczek Wojciech Biernat Radzisław Kordek Hanna Romańska Rafał Sądej

Citation

Reference

Related Paper

Citation Trend

Abstract:

We have recently demonstrated that, fibroblast growth factor 2 (FGFR2), signalling via ribosomal S6 kinase 2 (RSK2), promotes progression of breast cancer (BCa). Loss of progesterone receptor (PR), whose activity in BCa cells can be stimulated by growth factor receptors (GFRs), is associated with poor patient outcome. Here we showed that FGF7/FGFR2 triggered phosphorylation of PR at Ser294, PR ubiquitination and subsequent receptor`s degradation via the 26S proteasome pathway in BCa cells. We further demonstrated that RSK2 mediated FGF7/FGFR2-induced PR downregulation. In addition, a strong synergistic effect of FGF7 and progesterone (Pg), reflected in the enhanced anchorage-independent growth and cell migration, was observed. Analysis of clinical material demonstrated that expression of PR inversely correlated with activated RSK (RSK-P) (p = 0.016). Patients with RSK-P(+)/PR(-) tumours had 3.629-fold higher risk of recurrence (p = 0.002), when compared with the rest of the cohort. Moreover, RSK-P(+)/PR(-) phenotype was shown as an independent prognostic factor (p = 0.006). These results indicate that the FGF7/FGFR2-RSK2 axis promotes PR turnover and activity, which may sensitize BCa cells to stromal stimuli and contribute to the progression toward steroid hormone negative BCa.

Keywords:

Progesterone receptor

Topics:

Fibroblast Growth Factor Research

Estrogen and related hormone effects

Growth Hormone and Insulin-like Growth Factors

10.18632/oncotarget.13322

Cite

PDF